PLoS One:MicroRNA标志物或是亚洲印度表型2型糖尿病患者的特点

2015-08-20 佚名 生物谷

研究人员发现某些2型糖尿病患者“亚洲印度表型”的循环小分子核糖核酸(rna)生物标志物的作用特点——一种代谢性疾病被认为是印度韦达养生学疗法中的甜尿病。这项研究已经发表在PLoS One杂志上。 世界范围内多种组学技术正在调查并识别用于预防、诊断以及糖尿病方面治疗的生物标志物。近来,小分子核糖核酸被认为对非侵入性生物标记物有巨大潜力,用来预防、诊断和疾病预后,监测治疗和病人分层。这是因为循环小

研究人员发现某些2型糖尿病患者“亚洲印度表型”的循环小分子核糖核酸(rna)生物标志物的作用特点——一种代谢性疾病被认为是印度韦达养生学疗法中的甜尿病。这项研究已经发表在PLoS One杂志上。

世界范围内多种组学技术正在调查并识别用于预防、诊断以及糖尿病方面治疗的生物标志物。近来,小分子核糖核酸被认为对非侵入性生物标记物有巨大潜力,用来预防、诊断和疾病预后,监测治疗和病人分层。这是因为循环小分子核糖核酸在人类中已被证明是稳定的、可重复的、在健康个体和病理生理学改变之间是一致的,使有临床实用价值的疾病生物标志物具有潜在价值。

“尽管还需要进一步研究和前瞻性研究,但是在改变的循环小分子核糖核酸之间,miR-128从未在先前的研究中被提及,这似乎是印度人中的一个“新方向”,研究人员Muthuswamy Balasubramanyam & Viswanathan Mohan说。“考虑到miR-128在早期记录中被作为一种认知障碍的生物标志物,并在2型糖尿病的病因中存在神经系统成分,miR-128可能与认知功能障碍有关,抑郁症与代谢疾病相关”Balasubramanyam说。

“当小分子核糖核酸测量的相关技术统一标准时,预计特定的小分子核糖核酸既能单独应用又能作为一种潜在的个性化医疗工具或精准医药。”Balasubramanyam补充道。

原始出处:

Paramasivam Prabu,et al.Circulating MiRNAs of ‘Asian Indian Phenotype’ Identified in Subjects with Impaired Glucose Tolerance and Patients with Type 2 Diabetes.PLoS One. 2015 May 28;10(5):e0128372. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2015-09-08 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2015-08-22 zhouqu_8
  7. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2084131, encodeId=c0fa208413153, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Sep 08 05:33:00 CST 2015, time=2015-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857358, encodeId=c693185e3585d, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 22:33:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840851, encodeId=17491840851cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jul 29 20:33:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789703, encodeId=8a991e89703f2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 10 02:33:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383179, encodeId=c6df13831e935, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435670, encodeId=b3e014356e099, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473886, encodeId=308814e388643, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535116, encodeId=4e2d153511699, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2015-08-22 tastas

相关资讯

不能多喝可乐----可乐进入人体后变化图谱

疾病预防控制中心(CDC)的相关数据显示,在任何一天都有大约一半的美国居民饮用含糖饮料,其中青少年和年轻人消费量是最高的。一罐可乐中大约添加了10茶匙的糖。但世界卫生组织(WHO)推荐民众每日糖的食用量不要超过6茶匙,这意味着,即便我们每天只喝一罐可乐,每日糖类摄入量也是超标的。因此,含糖饮料的消费量居高不下会引起机体产生一系列健康问题。根据哈佛大学公共卫生学院的研究,每日饮用含糖饮料1-2罐的民

FASEB J:怀孕期间饮酒可增加胎儿患糖尿病的风险

怀孕期间饮酒可增加胎儿患糖尿病的风险!据昆士兰大学的一项新的研究表明,女性怀孕期间饮酒可大大增加后代中年早期2型糖尿病或肥胖的风险。该研究结果是在Karen Moritz 教授研究女性怀孕前及怀孕期间某些因素,尤其是饮酒,是如何影响其后代的健康的过程中发现的。使用小鼠建立实验模型对其进行研究,Moritz教授 及student Ms Emelie Gardebjer博士发现,小

Neurology:绝经后激素治疗,2型糖尿病女性患者大脑易萎缩

该项随机对照临床试验中旨在评估在65-79岁女性绝经后激素治疗(HT),2型糖尿病与脑容量的关系。在这项随机临床试验中患者分别接受平均5.6年的HT或安慰剂治疗。当试验进行到2.4年后,共1402名患者接受了头部磁共振(MRI)检查,有699名患者在4.7年后再次评估。使用线性模型对糖尿病、HT治疗以及大脑体积治疗情况进行评估。结果显示,患有糖尿病的女性组中,在随访期间,HT治疗组中总体大脑体积平

Diabetologia:运动干预2型糖尿病的代谢组学研究取得新进展

近日,中国科学院大连化学物理研究所生物技术研究部高分辨分离分析和代谢组学研究组(1808组)与丹麦哥本哈根大学临床和生物化学系及德国图宾根大学医学院合作,应用代谢组和转录组研究了糖尿病患者对运动的应答,相关研究结果在《糖尿病学》(Diabetologia)杂志作为“up front”文章发表。一直以来,人们认可运动对人类健康的好处,尤其是对2型糖尿病预防和治疗的作用。然而,2型糖尿病对运动过程中的

AHA、ADA 联合发布2型糖尿病患者心血管疾病预防的新指南

AHA、ADA 联合发布2型糖尿病患者心血管疾病预防的新指南近日,美国糖尿病学会(ADA)和美国心脏协会(AHA)联合发布了新修订的成人2型糖尿病患者心血管疾病预防的科学指南 。该指南(1999年最初发布,2007年开始修订更新)由美国国家心脏、肺和血液研究所高级研究员Caroline S Fox博士及约翰霍普金斯大学医学教授,Sherita Hill Golden博士共同主持编写,并于8月5日同

关注2型糖尿病患者死亡风险

2型糖尿病是患者进展为心血管(CV)和肾脏疾病的高危因素。近期美国学者对心-肾终点的2型糖尿病阿利吉仑试验(ALTITUDE)中CV和肾脏疾病事件负担以及随后的死亡风险进行了评估。研究者们对8561例2型糖尿病患者进行了随访,收集患者慢性肾脏疾病、心血管疾病或二者均存在的证据,包括至首次非致命性心血管或肾脏事件[心肌梗死(MI)、卒中、心力衰竭(HF)和终末期肾病(ESRD)]。利用时间校正多变量